Verona Pharma Stock (NASDAQ:VRNA)
Previous Close
$34.98
52W Range
$11.39 - $39.38
50D Avg
$30.60
200D Avg
$20.59
Market Cap
$2.84B
Avg Vol (3M)
$1.03M
Beta
0.44
Div Yield
-
VRNA Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
VRNA Performance
Peer Comparison
| Ticker | Company |
|---|---|
| AKRO | Akero Therapeutics, Inc. |
| XFOR | X4 Pharmaceuticals, Inc. |
| IDYA | IDEAYA Biosciences, Inc. |
| MREO | Mereo BioPharma Group plc |
| APLS | Apellis Pharmaceuticals, Inc. |
| DAWN | Day One Biopharmaceuticals, Inc. |
| VTYX | Ventyx Biosciences, Inc. |
| SNDX | Syndax Pharmaceuticals, Inc. |
| TERN | Terns Pharmaceuticals, Inc. |
| VKTX | Viking Therapeutics, Inc. |
| INZY | Inozyme Pharma, Inc. |
| MLTX | MoonLake Immunotherapeutics |
| ABOS | Acumen Pharmaceuticals, Inc. |
| PTGX | Protagonist Therapeutics, Inc. |
| MDGL | Madrigal Pharmaceuticals, Inc. |
| AMLX | Amylyx Pharmaceuticals, Inc. |